# OnCo record nct02486718 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02486718/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02486718", "NCT02486718" ;
  schema:name "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer ["@en ;
  schema:alternateName "IMpower010"@en ;
  schema:description "A phase 3 trial of Atezolizumab, Cisplatin, Vinorelbine in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02486718/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02486718>, <https://doi.org/10.1016/S0140-6736(21)02098-5>, <https://www.nice.org.uk/guidance/ta1071> ;
  onco:status "positive" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2015-10-31" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/keynote-091/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/alina/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/>, <https://onco.cc/key-papers/paper-nct02486718-ann-oncol-2023-update/> .